| pubmed-article:16804524 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16804524 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:16804524 | lifeskim:mentions | umls-concept:C0024623 | lld:lifeskim |
| pubmed-article:16804524 | lifeskim:mentions | umls-concept:C0023413 | lld:lifeskim |
| pubmed-article:16804524 | lifeskim:mentions | umls-concept:C0144576 | lld:lifeskim |
| pubmed-article:16804524 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
| pubmed-article:16804524 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:16804524 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:16804524 | lifeskim:mentions | umls-concept:C1446539 | lld:lifeskim |
| pubmed-article:16804524 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:16804524 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:16804524 | pubmed:dateCreated | 2006-7-12 | lld:pubmed |
| pubmed-article:16804524 | pubmed:abstractText | The aim of the study was to evaluate the response rate and safety of weekly paclitaxel (Taxol((R))) combination chemotherapy with UFT (tegafur, an oral 5-fluorouracil prodrug, and uracil at a 1 : 4 molar ratio) and leucovorin (LV) in patients with advanced gastric cancer. Patients with histologically confirmed, locally advanced or recurrent/metastatic gastric cancer were studied. Paclitaxel 1-h infusion at a dose of 100 mg m(-2) on days 1 and 8 and oral UFT 300 mg m(-2) day(-1) plus LV 90 mg day(-1) were given starting from day 1 for 14 days, followed by a 7-day period without treatment. Treatment was repeated every 21 days. From February 2003 to October 2004, 55 patients were enrolled. The median age was 62 years (range: 32-82). Among the 48 patients evaluated for tumour response, two achieved a complete response and 22 a partial response, with an overall response rate of 50% (95% confidence interval: 35-65%). All 55 patients were evaluated for survival and toxicities. Median time to progression and overall survival were 4.4 and 9.8 months, respectively. Major grade 3-4 toxicities were neutropenia in 25 patients (45%) and diarrhoea in eight patients (15%). Although treatment was discontinued owing to treatment-related toxicities in nine patients (16%), there was no treatment-related mortality. Weekly paclitaxel plus oral UFT/LV is effective, convenient, and well tolerated in treating patients with advanced gastric cancer. | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16804524 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16804524 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16804524 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16804524 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:16804524 | pubmed:issn | 0007-0920 | lld:pubmed |
| pubmed-article:16804524 | pubmed:author | pubmed-author:LiC PCP | lld:pubmed |
| pubmed-article:16804524 | pubmed:author | pubmed-author:ChenL TLT | lld:pubmed |
| pubmed-article:16804524 | pubmed:author | pubmed-author:WuM FMF | lld:pubmed |
| pubmed-article:16804524 | pubmed:author | pubmed-author:ChaoYY | lld:pubmed |
| pubmed-article:16804524 | pubmed:author | pubmed-author:HsiehR KRK | lld:pubmed |
| pubmed-article:16804524 | pubmed:author | pubmed-author:KaoW YWY | lld:pubmed |
| pubmed-article:16804524 | pubmed:author | pubmed-author:RehMM | lld:pubmed |
| pubmed-article:16804524 | pubmed:author | pubmed-author:ChengA LAL | lld:pubmed |
| pubmed-article:16804524 | pubmed:author | pubmed-author:YehK HKH | lld:pubmed |
| pubmed-article:16804524 | pubmed:author | pubmed-author:ChaoT YTY | lld:pubmed |
| pubmed-article:16804524 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16804524 | pubmed:day | 17 | lld:pubmed |
| pubmed-article:16804524 | pubmed:volume | 95 | lld:pubmed |
| pubmed-article:16804524 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16804524 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16804524 | pubmed:pagination | 159-63 | lld:pubmed |
| pubmed-article:16804524 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:16804524 | pubmed:meshHeading | pubmed-meshheading:16804524... | lld:pubmed |
| pubmed-article:16804524 | pubmed:meshHeading | pubmed-meshheading:16804524... | lld:pubmed |
| pubmed-article:16804524 | pubmed:meshHeading | pubmed-meshheading:16804524... | lld:pubmed |
| pubmed-article:16804524 | pubmed:meshHeading | pubmed-meshheading:16804524... | lld:pubmed |
| pubmed-article:16804524 | pubmed:meshHeading | pubmed-meshheading:16804524... | lld:pubmed |
| pubmed-article:16804524 | pubmed:meshHeading | pubmed-meshheading:16804524... | lld:pubmed |
| pubmed-article:16804524 | pubmed:meshHeading | pubmed-meshheading:16804524... | lld:pubmed |
| pubmed-article:16804524 | pubmed:meshHeading | pubmed-meshheading:16804524... | lld:pubmed |
| pubmed-article:16804524 | pubmed:meshHeading | pubmed-meshheading:16804524... | lld:pubmed |
| pubmed-article:16804524 | pubmed:meshHeading | pubmed-meshheading:16804524... | lld:pubmed |
| pubmed-article:16804524 | pubmed:meshHeading | pubmed-meshheading:16804524... | lld:pubmed |
| pubmed-article:16804524 | pubmed:meshHeading | pubmed-meshheading:16804524... | lld:pubmed |
| pubmed-article:16804524 | pubmed:meshHeading | pubmed-meshheading:16804524... | lld:pubmed |
| pubmed-article:16804524 | pubmed:meshHeading | pubmed-meshheading:16804524... | lld:pubmed |
| pubmed-article:16804524 | pubmed:meshHeading | pubmed-meshheading:16804524... | lld:pubmed |
| pubmed-article:16804524 | pubmed:meshHeading | pubmed-meshheading:16804524... | lld:pubmed |
| pubmed-article:16804524 | pubmed:meshHeading | pubmed-meshheading:16804524... | lld:pubmed |
| pubmed-article:16804524 | pubmed:meshHeading | pubmed-meshheading:16804524... | lld:pubmed |
| pubmed-article:16804524 | pubmed:meshHeading | pubmed-meshheading:16804524... | lld:pubmed |
| pubmed-article:16804524 | pubmed:meshHeading | pubmed-meshheading:16804524... | lld:pubmed |
| pubmed-article:16804524 | pubmed:meshHeading | pubmed-meshheading:16804524... | lld:pubmed |
| pubmed-article:16804524 | pubmed:meshHeading | pubmed-meshheading:16804524... | lld:pubmed |
| pubmed-article:16804524 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16804524 | pubmed:articleTitle | An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer. | lld:pubmed |
| pubmed-article:16804524 | pubmed:affiliation | Cancer Center, Taipei Veterans General Hospital, Taipei, Taiwan. | lld:pubmed |
| pubmed-article:16804524 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16804524 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:16804524 | pubmed:publicationType | Multicenter Study | lld:pubmed |
